Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of antibiotic treatment on gut flora and resistance genes in ESBL/VRE carriers
2019-000244-10Phase 4Active
- Sponsor
- Region Uppsala
- Start
- Oct 2019
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ciprofloxacin and vancomycin in Intestinal colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae and Vancomycin-resistant enterococci colonization, sponsored by Region Uppsala. Primary endpoints: Detection of resistant bacteria carriage by metagenomic method and Provocation of resistant bacteria carriage by antibiotic treatment. Started Oct 2019; status: active.
02
Drugs
ciprofloxacinvancomycin
03
Conditions
Intestinal colonization with extended-spectrum beta-lactamase-producing EnterobacteriaceaeVancomycin-resistant enterococci colonization
Beyond the preview
Go deeper on 2019-000244-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000244-10.